ARDELYX, INC. Interest Expense
ARDELYX, INC. (ARDX) reported Interest Expense of $2.36 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-02.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-02
- ARDELYX, INC. interest expense for the quarter ending 2024-03-31 was $2.36M, a 129.18% increase year-over-year.
- ARDELYX, INC. interest expense for the quarter ending 2023-12-31 was $1.74M, a 75.58% increase year-over-year.
- ARDELYX, INC. interest expense for the quarter ending 2023-09-30 was $1.11M, a 24.94% increase year-over-year.
- ARDELYX, INC. interest expense for the quarter ending 2023-06-30 was $1.07M, a 38.35% increase year-over-year.
- ARDELYX, INC. interest expense for fiscal 2023 was $4.95M, a 45.59% increase from fiscal 2022.
- ARDELYX, INC. interest expense for fiscal 2022 was $3.40M, a 24.48% decline from fiscal 2021.
- ARDELYX, INC. interest expense for fiscal 2021 was $4.50M, a 11.71% decline from fiscal 2020.
- ARDELYX, INC. interest expense for fiscal 2020 was $5.10M, a 10.95% decline from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 3 month as first filed | Interest Expense 6 month | Interest Expense 6 month as first filed | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|---|---|
| 2024-03-31 | $2.36M 10-Q · filed 2024-05-02 | $4.10M derived: sum of 2 quarters · filed 2024-05-02 | $5.20M derived: sum of 3 quarters · filed 2024-05-02 | $6.28M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2023-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.85M derived: sum of 2 quarters · filed 2024-02-22 | $3.92M derived: sum of 3 quarters · filed 2024-02-22 | $4.95M 10-K · filed 2024-02-22 | ||
| 2023-09-30 | $1.11M 10-Q · filed 2023-10-31 | $2.18M derived: sum of 2 quarters · filed 2023-10-31 | $3.21M 10-Q · filed 2023-10-31 | $4.20M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2023-06-30 | $1.07M 10-Q · filed 2023-08-02 | $2.10M 10-Q · filed 2023-08-02 | $3.09M derived: sum of 3 quarters · filed 2024-05-02 | $3.98M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-02 | $2.02M derived: sum of 2 quarters · filed 2024-05-02 | $2.90M derived: sum of 3 quarters · filed 2024-05-02 | $3.68M derived: sum of 4 quarters · filed 2024-05-02 | ||
| 2022-12-31 | $991.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $1.88M derived: sum of 2 quarters · filed 2024-02-22 | $2.65M derived: sum of 3 quarters · filed 2024-02-22 | $3.40M 10-K · filed 2024-02-22 | ||
| 2022-09-30 | $886.00K 10-Q · filed 2023-10-31 | $1.66M derived: sum of 2 quarters · filed 2023-10-31 | $2.41M 10-Q · filed 2023-10-31 | $3.39M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2022-06-30 | $777.00K 10-Q · filed 2023-08-02 | $787.00K 10-Q · filed 2022-08-04 | $1.52M 10-Q · filed 2023-08-02 | $1.53M 10-Q · filed 2022-08-04 | $2.51M derived: sum of 3 quarters · filed 2024-02-22 | $3.72M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $746.00K 10-Q · filed 2023-05-03 | $1.73M derived: sum of 2 quarters · filed 2024-02-22 | $2.95M derived: sum of 3 quarters · filed 2024-02-22 | $4.15M derived: sum of 4 quarters · filed 2024-02-22 | ||
| 2021-12-31 | $984.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.20M derived: sum of 2 quarters · filed 2024-02-22 | $3.40M derived: sum of 3 quarters · filed 2024-02-22 | $4.50M 10-K · filed 2024-02-22 | ||
| 2021-09-30 | $1.22M 10-Q · filed 2022-11-03 | $2.42M derived: sum of 2 quarters · filed 2022-11-03 | $3.52M 10-Q · filed 2022-11-03 | $4.83M derived: sum of 4 quarters · filed 2023-03-02 | ||
| 2021-06-30 | $1.20M 10-Q · filed 2022-08-04 | $2.30M 10-Q · filed 2022-08-04 | $3.62M derived: sum of 3 quarters · filed 2023-03-02 | $4.82M derived: sum of 4 quarters · filed 2023-03-02 | ||
| 2021-03-31 | $1.10M 10-Q · filed 2022-05-05 | $2.41M derived: sum of 2 quarters · filed 2023-03-02 | $3.62M derived: sum of 3 quarters · filed 2023-03-02 | $4.84M derived: sum of 4 quarters · filed 2023-03-02 | ||
| 2020-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $2.52M derived: sum of 2 quarters · filed 2023-03-02 | $3.74M derived: sum of 3 quarters · filed 2023-03-02 | $5.10M 10-K · filed 2023-03-02 | ||
| 2020-09-30 | $1.20M 10-Q · filed 2021-11-12 | $2.43M derived: sum of 2 quarters · filed 2021-11-12 | $3.79M 10-Q · filed 2021-11-12 | $5.18M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $1.23M 10-Q · filed 2021-08-13 | $2.58M 10-Q · filed 2021-08-13 | $3.98M derived: sum of 3 quarters · filed 2022-02-28 | $5.42M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $1.36M 10-Q · filed 2021-05-06 | $2.75M derived: sum of 2 quarters · filed 2022-02-28 | $4.20M derived: sum of 3 quarters · filed 2022-02-28 | $5.65M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.84M derived: sum of 2 quarters · filed 2022-02-28 | $4.29M derived: sum of 3 quarters · filed 2022-02-28 | $5.73M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $1.44M 10-Q · filed 2020-11-05 | $2.89M derived: sum of 2 quarters · filed 2020-11-05 | $4.33M 10-Q · filed 2020-11-05 | $5.77M derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2019-06-30 | $1.45M 10-Q · filed 2020-08-06 | $2.88M 10-Q · filed 2020-08-06 | $4.32M derived: sum of 3 quarters · filed 2021-03-08 | $5.73M derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2019-03-31 | $1.43M 10-Q · filed 2020-05-07 | $2.87M derived: sum of 2 quarters · filed 2021-03-08 | $4.28M derived: sum of 3 quarters · filed 2021-03-08 | $4.97M derived: sum of 4 quarters · filed 2021-03-08 | ||
| 2018-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $2.84M derived: sum of 2 quarters · filed 2021-03-08 | $3.53M derived: sum of 3 quarters · filed 2021-03-08 | $3.53M 10-K · filed 2021-03-08 | ||
| 2018-09-30 | $1.40M 10-Q · filed 2019-11-06 | $2.10M derived: sum of 2 quarters · filed 2019-11-06 | $2.10M 10-Q · filed 2019-11-06 | |||
| 2018-06-30 | $692.00K 10-Q · filed 2019-08-09 | $692.00K 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |